Discovery of hematopoietic progenitor kinase 1 inhibitors using machine learning-based screening and free energy perturbation.

Journal: Journal of biomolecular structure & dynamics
PMID:

Abstract

Hematopoietic progenitor kinase 1 (HPK1) is a key negative regulator of T-cell receptor (TCR) signaling and a promising target for cancer immunotherapy. The development of novel HPK1 inhibitors is challenging yet promising. In this study, we used a combination of machine learning (ML)-based virtual screening and free energy perturbation (FEP) calculations to identify novel HPK1 inhibitors. ML-based screening yielded 10 potent HPK1 inhibitors (IC < 1 μM). The FEP-guided modification of the in-house false-positive hit, , revealed that a single key atom change could trigger activity cliffs. The resulting was a potent HPK1 inhibitor (IC = 2.1 nM) and potently inhibited cellular HPK1 signaling and enhanced T-cell function. Molecular dynamics (MD) simulations and ADME predictions confirmed as candidate compound. This study provides new strategies and chemical scaffolds for HPK1 inhibitor development.

Authors

  • Dazhi Feng
    Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
  • Bo Liu
    Wuhan United Imaging Healthcare Surgical Technology Co., Ltd., Wuhan, China.
  • Zhiwei Chen
    School of Life Sciences, Shandong University of Technology, Zibo 255049, PR China.
  • Jinyi Xu
    State Key Laboratory of Natural Medicines and Department of Medicinal Chemistry, China Pharmaceutical University, Nanjing, China.
  • Meiyu Geng
    Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
  • Wenhu Duan
    Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
  • Jing Ai
    Division of Antitumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.
  • Hefeng Zhang
    Department of Medicinal Chemistry, Shanghai Institute of Materia Medica (SIMM), Chinese Academy of Sciences, Shanghai, China.